Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic, Harvard Medical School to Use Michael J. Fox Funds for Parkinson’s Dx Research

NEW YORK (GenomeWeb News) – DiaGenic and researchers at Harvard Medical School will use funding from the Michael J. Fox Foundation to develop a blood-based test for early detection of Parkinson’s disease.
 
DiaGenic will work with Clemens Scherzer, an assistant professor of neurology at Brigham and Women’s Hospital and Harvard Medical School, who has led the MJFF-funded Harvard PD Biomarker Study for three years.
 
The study partners will identify and validate gene expression signatures for Parkinson’s using peripheral blood samples that have already been collected for the Harvard study. Signatures will be incorporated into a test to run on a standard platform that will be combined with DiaGenics’ analysis software.
 
The grant will cover the initial funding for the study, the company said, but the amount of the gift was not disclosed. 
 
Scherzer said in a statement that he is “optimistic that the use of peripheral gene expression will prove valuable for the early detection of neurological disorders.”

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.